Futura Medical yesterday announced the long-awaited commercial partnership for its MED2002 non-prescription topical treatment for erectile dysfunction, confirming the identity of its “major global pharmaceutical group” partner as GlaxoSmithKline. Futura has concurrently raised a further £3.3m net to support the ongoing development costs and expand its R&D programme in new areas.

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here